HER3 NSCLC Text Module

CME

Exploring the Clinical Landscape of Novel HER3-Targeted Treatments for Advanced NSCLC

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: November 06, 2023

Expiration: November 05, 2024

Rebecca S. Heist
Rebecca S. Heist, MD, MPH

Activity

Progress
1
Course Completed

Introduction

In this module, Rebecca S. Heist, MD, MPH, summarizes the current state of clinical development of agents targeting HER3 for the treatment of patients with advanced non-small-cell lung cancer (NSCLC), including those with EGFR or NRG1 mutations.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. One question will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with NSCLC do you provide care for in a typical month?

Which of the following is a true statement about potential adverse events (AEs) with patritumab deruxtecan that the healthcare team should understand to develop appropriate strategies to identify and manage associated treatment-related adverse event (TRAE)?